Back to Search Start Over

Dihydroartemisinin Affects STAT3/DDA1 Signaling Pathway and Reverses Breast Cancer Resistance to Cisplatin.

Authors :
Zhang, Jing
Li, Yang
Wang, Ji-Guo
Feng, Jing-Yu
Huang, Guo-Dong
Luo, Chang-Guo
Source :
American Journal of Chinese Medicine. 2023, Vol. 51 Issue 2, p445-459. 15p.
Publication Year :
2023

Abstract

Dihydroartemisinin (DHA) has anticancer effects on multiple tumors, including those associated with breast cancer. This study aimed to investigate the mechanism causing DHA-reversing cisplatin (DDP) resistance in breast cancer. Relative mRNA and protein levels were tested using a qRT-PCR and western blot assay. Cell proliferation, viability, and apoptosis were evaluated using colony formation, MTT, and flow cytometry assays, respectively. Interaction of STAT3 and DDA1 was measured via a dual-luciferase reporter assay. The results showed that DDA1 and p-STAT3 levels were dramatically elevated in DDP-resistant cells. DHA treatment repressed proliferation and induced apoptosis of DDP-resistant cells by suppressing STAT3 phosphorylation; the inhibition ability was positively proportional to the DHA concentration. DDA1 knockdown inhibited cyclin expression, promoted G0/G1 phase arrest, restrained cell proliferation, and induced apoptosis of DDP-resistant cells. Furthermore, knockdown of STAT3 restrained proliferation and induced apoptosis and G0/G1 cell cycle arrest of DDP-resistant cells by targeting DDA1. DHA could restrain tumor proliferation of breast cancer via enhancing drug sensitivity of DDP-resistant cells through the STAT3/DDA1 signaling pathway. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
0192415X
Volume :
51
Issue :
2
Database :
Academic Search Index
Journal :
American Journal of Chinese Medicine
Publication Type :
Academic Journal
Accession number :
162755783
Full Text :
https://doi.org/10.1142/S0192415X23500234